secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-011069
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M
----------------------------------------------------------------------

- Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.
- Cash and equivalents $1.8M at March 31, 2025, down from $5.9M at Dec 31, 2024.
- Phase 3 trial for Ameluz in actinic keratoses on extremities, neck and trunk enrolled final patient; Phase 3 sBCC study completed 1-year follow-up.
- Phase 2b study for Ameluz in moderate to severe acne vulgaris completed patient enrollment.
- Patent approval extended Ameluz protection to December 2043 for revised formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/0001641172-25-011069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer